These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 26993335)

  • 1. Status of vaccine research and development of vaccines for HIV-1.
    Safrit JT; Fast PE; Gieber L; Kuipers H; Dean HJ; Koff WC
    Vaccine; 2016 Jun; 34(26):2921-2925. PubMed ID: 26993335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accelerating the development of a safe and effective HIV vaccine: HIV vaccine case study for the Decade of Vaccines.
    Koff WC; Russell ND; Walport M; Feinberg MB; Shiver JW; Karim SA; Walker BD; McGlynn MG; Nweneka CV; Nabel GJ
    Vaccine; 2013 Apr; 31 Suppl 2():B204-8. PubMed ID: 23598483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospects for a globally effective HIV-1 vaccine.
    Excler JL; Robb ML; Kim JH
    Vaccine; 2015 Nov; 33 Suppl 4():D4-12. PubMed ID: 26100921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost.
    Hulot SL; Korber B; Giorgi EE; Vandergrift N; Saunders KO; Balachandran H; Mach LV; Lifton MA; Pantaleo G; Tartaglia J; Phogat S; Jacobs B; Kibler K; Perdiguero B; Gomez CE; Esteban M; Rosati M; Felber BK; Pavlakis GN; Parks R; Lloyd K; Sutherland L; Scearce R; Letvin NL; Seaman MS; Alam SM; Montefiori D; Liao HX; Haynes BF; Santra S
    J Virol; 2015 Jun; 89(12):6462-80. PubMed ID: 25855741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
    Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
    J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem.
    Koff WC
    Vaccine; 2012 Jun; 30(29):4310-5. PubMed ID: 22100891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV Vaccine: Recent Advances, Current Roadblocks, and Future Directions.
    Rubens M; Ramamoorthy V; Saxena A; Shehadeh N; Appunni S
    J Immunol Res; 2015; 2015():560347. PubMed ID: 26579546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PUBLIC HEALTH. Toward an HIV vaccine: A scientific journey.
    Fauci AS; Marston HD
    Science; 2015 Jul; 349(6246):386-7. PubMed ID: 26206922
    [No Abstract]   [Full Text] [Related]  

  • 10. Challenges for structure-based HIV vaccine design.
    Schief WR; Ban YE; Stamatatos L
    Curr Opin HIV AIDS; 2009 Sep; 4(5):431-40. PubMed ID: 20048708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
    Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
    J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits.
    Jiang X; Totrov M; Li W; Sampson JM; Williams C; Lu H; Wu X; Lu S; Wang S; Zolla-Pazner S; Kong XP
    J Virol; 2016 Dec; 90(24):11007-11019. PubMed ID: 27707920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design.
    Sadanand S; Suscovich TJ; Alter G
    Annu Rev Med; 2016; 67():185-200. PubMed ID: 26565674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broadly neutralizing antibodies against HIV-1: templates for a vaccine.
    van Gils MJ; Sanders RW
    Virology; 2013 Jan; 435(1):46-56. PubMed ID: 23217615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospects for a Globally Effective HIV-1 Vaccine.
    Excler JL; Robb ML; Kim JH
    Am J Prev Med; 2015 Dec; 49(6 Suppl 4):S307-18. PubMed ID: 26590431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Vaccines against HIV].
    Holm-Hansen C
    Tidsskr Nor Laegeforen; 2006 Nov; 126(23):3117-20. PubMed ID: 17160118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New approaches to HIV vaccine development.
    Haynes BF
    Curr Opin Immunol; 2015 Aug; 35():39-47. PubMed ID: 26056742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. All eyes on the next generation of HIV vaccines: strategies for inducing a broadly neutralizing antibody response.
    Ahlers JD
    Discov Med; 2014 Apr; 17(94):187-99. PubMed ID: 24759623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A brief history of the global effort to develop a preventive HIV vaccine.
    Esparza J
    Vaccine; 2013 Aug; 31(35):3502-18. PubMed ID: 23707164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variable epitope libraries: new vaccine immunogens capable of inducing broad human immunodeficiency virus type 1-neutralizing antibody response.
    Charles-Niño C; Pedroza-Roldan C; Viveros M; Gevorkian G; Manoutcharian K
    Vaccine; 2011 Jul; 29(32):5313-21. PubMed ID: 21600948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.